PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 145 filers reported holding PROTAGONIST THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.11 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $716,623 | -37.6% | 42,963 | +3.3% | 0.00% | 0.0% |
| Q2 2023 | $1,148,688 | -46.9% | 41,589 | -55.8% | 0.00% | -66.7% |
| Q1 2023 | $2,163,311 | +42.2% | 94,057 | -32.5% | 0.00% | +50.0% |
| Q4 2022 | $1,520,842 | +23.2% | 139,399 | -4.8% | 0.00% | 0.0% |
| Q3 2022 | $1,234,648 | +801.2% | 146,459 | +743.3% | 0.00% | – |
| Q2 2022 | $137,000 | -66.7% | 17,368 | 0.0% | 0.00% | -100.0% |
| Q1 2022 | $411,000 | -30.8% | 17,368 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $594,000 | +92.2% | 17,368 | -0.4% | 0.00% | 0.0% |
| Q3 2021 | $309,000 | -57.6% | 17,437 | +7.3% | 0.00% | 0.0% |
| Q2 2021 | $729,000 | +86.4% | 16,250 | +7.7% | 0.00% | 0.0% |
| Q1 2021 | $391,000 | +48.1% | 15,094 | +15.5% | 0.00% | 0.0% |
| Q4 2020 | $264,000 | +34.7% | 13,071 | +30.4% | 0.00% | – |
| Q3 2020 | $196,000 | – | 10,026 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $19,373,000 | 4.95% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $17,881,000 | 2.10% |
| Finepoint Capital LP | 735,126 | $5,815,000 | 2.01% |
| Altium Capital Management LP | 365,100 | $2,888,000 | 1.16% |
| RTW INVESTMENTS, LP | 4,794,499 | $37,924,000 | 0.98% |
| Amitell Capital Pte Ltd | 50,129 | $397,000 | 0.90% |
| COWEN AND COMPANY, LLC | 1,065,724 | $8,430,000 | 0.81% |
| Tri Locum Partners LP | 155,000 | $1,226,000 | 0.50% |
| BVF INC/IL | 1,106,838 | $8,755,000 | 0.42% |
| HighVista Strategies LLC | 46,459 | $367,000 | 0.22% |